Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln

Reuters
11/13
Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln

Overview

  • Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement

  • Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year

  • Palatin completes $18.2 mln public offering, regains NYSE American compliance

Outlook

  • Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026

  • Palatin expects mid-2026 IND filing for next-gen MC4R agonists

  • Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity

Result Drivers

  • BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement

  • PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

$4.26

Press Release: ID:nPnf1Qmja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10